As Zyn­lon­ta sales dis­ap­point, ADC Ther­a­peu­tics cuts staff and pre­clin­i­cal pro­grams

ADC Ther­a­peu­tics an­nounced Tues­day morn­ing that it was lay­ing off more than 50 staffers and stop­ping work on two pre­clin­i­cal can­cer pro­grams.

ADC plans to lay off 17% of its work­force — or ap­prox­i­mate­ly 54 of its 317 em­ploy­ees, as of the end of 2022. The biotech not­ed it’s in­clud­ing con­trac­tors in its lay­off count.

The Swiss biotech is al­so stop­ping in­vest­ment in AD­CT-212, a pre­clin­i­cal an­ti­body-drug con­ju­gate for prostate can­cer, and AD­CT-701, which it had hoped to test in neu­roen­docrine tu­mors.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN